Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 149,700 shares, a growth of 6.0% from the November 30th total of 141,200 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 16,500 shares, the short-interest ratio is presently 9.1 days.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. RODMAN&RENSHAW raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company.

Eupraxia Pharmaceuticals Price Performance

Eupraxia Pharmaceuticals stock opened at $3.13 on Friday. The stock has a market cap of $85.39 million and a PE ratio of -4.35. The stock’s fifty day moving average is $3.14 and its two-hundred day moving average is $2.78. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $5.58.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.